Cancer chromosome breakpoints and common fragile sites induced by aphidicolin. 1984

F Hecht, and T W Glover

A new class of fragile sites termed common fragile sites is induced by aphidicolin, an inhibitor of DNA polymerase alpha. Analysis of these common fragile sites and cancer chromosome breakpoints indicates that eight fragile sites are in bands with cancer breakpoints. This is unlikely to be due to chance (p less than 0.01). Common fragile sites are in both bands where breaks occur in carcinoma of the lung and in carcinoma of the ovary. Common fragile sites are in bands with breaks leading to constitutional chromosome abnormalities associated with cancer: hereditary renal cell carcinoma and aniridia-Wilms' tumor complex. Common fragile sites, thus, may predispose to chromosome breaks and rearrangements in cancer.

UI MeSH Term Description Entries
D002873 Chromosome Fragility Susceptibility of chromosomes to breakage leading to translocation; CHROMOSOME INVERSION; SEQUENCE DELETION; or other CHROMOSOME BREAKAGE related aberrations. Chromosomal Fragility,Fragility, Chromosomal,Fragility, Chromosome
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D004224 Diterpenes Twenty-carbon compounds derived from MEVALONIC ACID or deoxyxylulose phosphate. Diterpene,Diterpenes, Cembrane,Diterpenes, Labdane,Diterpenoid,Labdane Diterpene,Norditerpene,Norditerpenes,Norditerpenoid,Cembranes,Diterpenoids,Labdanes,Norditerpenoids,Cembrane Diterpenes,Diterpene, Labdane,Labdane Diterpenes
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016590 Aphidicolin An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells. Aphidicolin, (3-S-(3alpha,4beta,4abeta,6aalpha,8alpha,9alpha,11aalpha,11balpha))-Isomer,ICI-69653,NSC-234714,NSC-351140,ICI 69653,ICI69653,NSC 234714,NSC 351140,NSC234714,NSC351140
D043283 Chromosome Fragile Sites Specific loci that show up during KARYOTYPING as a gap (an uncondensed stretch in closer views) on a CHROMATID arm after culturing cells under specific conditions. These sites are associated with an increase in CHROMOSOME FRAGILITY. They are classified as common or rare, and by the specific culture conditions under which they develop. Fragile site loci are named by the letters "FRA" followed by a designation for the specific chromosome, and a letter which refers to which fragile site of that chromosome (e.g. FRAXA refers to fragile site A on the X chromosome. It is a rare, folic acid-sensitive fragile site associated with FRAGILE X SYNDROME.) Fragile Sites, Chromosome,Chromosome Fragile Site,Fragile Site, Chromosome,Site, Chromosome Fragile,Sites, Chromosome Fragile
D019384 Nucleic Acid Synthesis Inhibitors Compounds that inhibit cell production of DNA or RNA. DNA Polymerase Inhibitor,DNA Synthesis Inhibitor,DNA Synthesis Inhibitors,Nucleic Acid Synthesis Inhibitor,RNA Synthesis Inhibitor,RNA Synthesis Inhibitors,DNA Polymerase Inhibitors,Inhibitors, DNA Synthesis,Inhibitors, Nucleic Acid Synthesis,Inhibitors, RNA Synthesis,Inhibitor, DNA Polymerase,Inhibitor, DNA Synthesis,Inhibitor, RNA Synthesis,Inhibitors, DNA Polymerase,Polymerase Inhibitor, DNA,Polymerase Inhibitors, DNA,Synthesis Inhibitor, DNA,Synthesis Inhibitor, RNA,Synthesis Inhibitors, DNA,Synthesis Inhibitors, RNA

Related Publications

F Hecht, and T W Glover
August 1989, Human genetics,
F Hecht, and T W Glover
March 1988, Cancer genetics and cytogenetics,
F Hecht, and T W Glover
June 1984, Cancer genetics and cytogenetics,
F Hecht, and T W Glover
May 1985, Clinical genetics,
F Hecht, and T W Glover
July 1985, Clinical genetics,
F Hecht, and T W Glover
July 1992, Human genetics,
F Hecht, and T W Glover
July 1992, Cancer genetics and cytogenetics,
Copied contents to your clipboard!